BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fraggetta F, Pelosi G, Cafici A, Scollo P, Nuciforo P, Viale G. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch. 2003;443:782-786. [PMID: 14576939 DOI: 10.1007/s00428-003-0910-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Vang R, Gown AM, Wu LS, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 2006;19:1421-8. [PMID: 16980943 DOI: 10.1038/modpathol.3800698] [Cited by in Crossref: 115] [Cited by in F6Publishing: 96] [Article Influence: 7.2] [Reference Citation Analysis]
2 Dundr P, Singh N, Nožičková B, Němejcová K, Bártů M, Stružinská I. Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics. Diagn Pathol 2021;16:20. [PMID: 33706757 DOI: 10.1186/s13000-021-01079-2] [Reference Citation Analysis]
3 Bing Z, Pasha T, Tomaszewski JE, Zhang P. CDX2 Expression in Yolk Sac Component of Testicular Germ Cell Tumors. Int J Surg Pathol 2009;17:373-7. [DOI: 10.1177/1066896909338598] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
4 Goldstein NS, Bosler DS. Immunohistochemistry of the Gastrointestinal Tract, Pancreas, Bile Ducts, Gallbladder and Liver. Diagnostic Immunohistochemistry. Elsevier; 2006. pp. 442-508. [DOI: 10.1016/b978-0-443-06652-8.50019-3] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
5 Saad RS, Ismiil N, Dubé V, Nofech-Mozes S, Khalifa MA. CDX-2 expression is a common event in primary intestinal-type endocervical adenocarcinoma. Am J Clin Pathol. 2009;132:531-538. [PMID: 19762530 DOI: 10.1309/ajcp7e5asgoenpfp] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
6 Chu PG, Chung L, Weiss LM, Lau SK. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol 2011;35:1830-6. [PMID: 21881489 DOI: 10.1097/PAS.0b013e3182299c25] [Cited by in Crossref: 68] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
7 Li Z, Roth R, Rock JB, Lehman A, Marsh WL, Suarez A, Frankel WL. Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms. Am J Clin Pathol 2017;147:484-91. [PMID: 28340228 DOI: 10.1093/ajcp/aqx023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
8 Pinto PBC, Derchain SFM, Andrade LALDA. Metastatic Mucinous Carcinomas in the Ovary: A Practical Approach to Diagnosis Related to Gross Aspects and to Immunohistochemical Evaluation. International Journal of Gynecological Pathology 2012;31:313-8. [DOI: 10.1097/pgp.0b013e31823f844d] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
9 Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS, Lee KY. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol. 2010;40:208-213. [PMID: 19926591 DOI: 10.1093/jjco/hyp150] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
10 Logani S, Oliva E, Arnell PM, Amin MB, Young RH. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005;18:19-25. [PMID: 15389251 DOI: 10.1038/modpathol.3800260] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
11 Barbareschi M, Roldo C, Zamboni G, Capelli P, Cavazza A, Macri E, Cangi MG, Chilosi M, Doglioni C. CDX-2 Homeobox Gene Product Expression in Neuroendocrine Tumors: Its Role as a Marker of Intestinal Neuroendocrine Tumors. American Journal of Surgical Pathology 2004;28:1169-76. [DOI: 10.1097/01.pas.0000131531.75602.b9] [Cited by in Crossref: 74] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
12 Al-nafussi A. Ovarian epithelial tumours: common problems in diagnosis. Current Diagnostic Pathology 2004;10:473-99. [DOI: 10.1016/j.cdip.2004.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Hart WR. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int. 2005;55:231-243. [PMID: 15871720 DOI: 10.1111/j.1440-1827.2005.01819.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
14 Zeng HA, Cartun R, Ricci A. Potential Diagnostic Utility of CDX-2 Immunophenotyping in Extramammary Paget's Disease. Applied Immunohistochemistry & Molecular Morphology 2005;13:342-6. [DOI: 10.1097/01.pai.0000163989.12896.d2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
15 Saad RS, Ghorab Z, Khalifa MA, Xu M. CDX2 as a marker for intestinal differentiation: Its utility and limitations. World J Gastrointest Surg 2011; 3(11): 159-166 [PMID: 22180832 DOI: 10.4240/wjgs.v3.i11.159] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
16 Crobach S, Ruano D, van Eijk R, Fleuren GJ, Minderhout I, Snowdowne R, Tops C, van Wezel T, Morreau H. Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue. J Mol Diagn 2015;17:193-200. [PMID: 25545608 DOI: 10.1016/j.jmoldx.2014.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
17 Huang LP, Yu YH, Sheng C, Wang SH. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22:1170-1176. [PMID: 22810971 DOI: 10.1097/igc.0b013e318261d89c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
18 Halimi SA, Maeda D, Ushiku-Shinozaki A, Goto A, Oda K, Osuga Y, Fujii T, Ushiku T, Fukayama M. Comprehensive immunohistochemical analysis of the gastrointestinal and Müllerian phenotypes of 139 ovarian mucinous cystadenomas. Hum Pathol 2021;109:21-30. [PMID: 33275953 DOI: 10.1016/j.humpath.2020.11.011] [Reference Citation Analysis]
19 Herawi M, De Marzo AM, Kristiansen G, Epstein JI. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Hum Pathol. 2007;38:72-78. [PMID: 16949907 DOI: 10.1016/j.humpath.2006.06.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
20 Jiang Y, Zhang Y, Li F, Du X, Zhang J. CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p. Tumour Biol 2016;37:1041-9. [PMID: 26269116 DOI: 10.1007/s13277-015-3900-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
21 Inamura K, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Fukayama M, Ishikawa Y. Pulmonary Adenocarcinomas With Enteric Differentiation: Histologic and Immunohistochemical Characteristics Compared With Metastatic Colorectal Cancers and Usual Pulmonary Adenocarcinomas. American Journal of Surgical Pathology 2005;29:660-5. [DOI: 10.1097/01.pas.0000160438.00652.8b] [Cited by in Crossref: 113] [Cited by in F6Publishing: 88] [Article Influence: 6.6] [Reference Citation Analysis]
22 Sullivan LM, Smolkin ME, Frierson HF Jr, Galgano MT. Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology. Am J Surg Pathol 2008;32:1608-12. [PMID: 18753946 DOI: 10.1097/PAS.0b013e31816d71c4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
23 Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, Smith AN, Gardiner-Garden M, Biankin AV, Baron-Hay S, Scott C, Ward RL, Fink D, Hacker NF, Sutherland RL, O'Brien PM. Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. J Clin Pathol 2007;60:622-6. [PMID: 16822880 DOI: 10.1136/jcp.2005.034223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
24 Kameoka Y, Kitazawa R, Ariasu K, Tachibana R, Mizuno Y, Haraguchi R, Kitazawa S. Reactivation of CDX2 in Gastric Cancer as Mark for Gene Silencing Memory. Acta Histochem Cytochem 2015;48:115-24. [PMID: 26379313 DOI: 10.1267/ahc.15014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Lee MJ, Vogt AP, Hsiao W, Osunkoya AO. CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules. Tumour Biol 2012;33:2185-8. [PMID: 22895825 DOI: 10.1007/s13277-012-0479-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
26 Oz Atalay F, Aytac Vuruskan B, Vuruskan H. CDX2 immunostaining in primary and metastatic germ cell tumours of the testis. J Int Med Res 2016;44:1323-30. [PMID: 28322096 DOI: 10.1177/0300060516665472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Heatley MK. Immunohistochemical and functional biomarkers of value in female genital tract lesions: a systematic review with statistical meta-analysis. Int J Gynecol Pathol 2007;26:177-9. [PMID: 17413986 DOI: 10.1097/pgp.0b013e318031049e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Miura K, Ishida K, Fujibuchi W, Ito A, Niikura H, Ogawa H, Sasaki I. Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database. Surg Today 2012;42:515-25. [PMID: 22441574 DOI: 10.1007/s00595-012-0167-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Pinto R, Barros R, Pereira-Castro I, Mesquita P, da Costa LT, Bennett EP, Almeida R, David L. CDX2 homeoprotein is involved in the regulation of ST6GalNAc-I gene in intestinal metaplasia. Lab Invest 2015;95:718-27. [PMID: 25867765 DOI: 10.1038/labinvest.2015.52] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
30 Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB. Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases: . International Journal of Gynecological Pathology 2010;29:99-107. [DOI: 10.1097/pgp.0b013e3181bbbcc1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
31 McCluggage WG, Shah R, Connolly LE, McBride HA. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol. 2008;27:92-100. [PMID: 18156982 DOI: 10.1097/pgp.0b013e31815698e7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
32 Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med 2007;9:1-12. [DOI: 10.1017/s1462399407000324] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
33 Horn LC, Einenkel J, Handzel R, Höhn AK. [Morphology of secondary ovarian tumors and metastases]. Pathologe 2014;35:336-47. [PMID: 24859239 DOI: 10.1007/s00292-014-1907-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Kuhn E, Ayhan A. Diagnostic immunohistochemistry in gynaecological neoplasia: a brief survey of the most common scenarios. J Clin Pathol 2018;71:98-109. [PMID: 29183921 DOI: 10.1136/jclinpath-2017-204787] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Park KJ, Bramlage MP, Ellenson LH, Pirog EC. Immunoprofile of Adenocarcinomas of the Endometrium, Endocervix, and Ovary With Mucinous Differentiation. Applied Immunohistochemistry & Molecular Morphology 2009;17:8-11. [DOI: 10.1097/pai.0b013e318174f012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
36 McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43:420-432. [PMID: 21716157 DOI: 10.1097/pat.0b013e328348a6e7] [Cited by in Crossref: 265] [Cited by in F6Publishing: 137] [Article Influence: 24.1] [Reference Citation Analysis]
37 Muinao T, Pal M, Deka Boruah HP. Origins based clinical and molecular complexities of epithelial ovarian cancer. Int J Biol Macromol 2018;118:1326-45. [PMID: 29890249 DOI: 10.1016/j.ijbiomac.2018.06.036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
38 Saqi A, Alexis D, Remotti F, Bhagat G. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol. 2005;123:394-404. [PMID: 15716236 DOI: 10.1309/ukn6pvrkxhg422da] [Cited by in Crossref: 93] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
39 Shah SS, Wu TT, Torbenson MS, Chandan VS. Aberrant CDX2 expression in hepatocellular carcinomas: An important diagnostic pitfall. Hum Pathol. 2017;64:13-18. [PMID: 28089540 DOI: 10.1016/j.humpath.2016.12.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
40 R. Stewart CJ, Tsukamoto T, Cooke B, Leung YC, Hammond IG. Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour. Pathology 2006;38:534-8. [DOI: 10.1080/00313020601024078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
41 Heatley MK. Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: a systematic review with statistical meta-analysis. Histopathology 2008;52:267-76. [DOI: 10.1111/j.1365-2559.2007.02824.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
42 Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.Histopathology. 2006;49:381-387. [PMID: 16978201 DOI: 10.1111/j.1365-2559.2006.02512.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
43 Kim MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Korean Med Sci. 2005;20:643-648. [PMID: 16100458 DOI: 10.3346/jkms.2005.20.4.643] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
44 Vang R, Gown AM, Zhao C, Barry TS, Isacson C, Richardson MS, Ronnett BM. Ovarian Mucinous Tumors Associated With Mature Cystic Teratomas: Morphologic and Immunohistochemical Analysis Identifies a Subset of Potential Teratomatous Origin That Shares Features of Lower Gastrointestinal Tract Mucinous Tumors More Commonly Encountered as Secondary Tumors in the Ovary. American Journal of Surgical Pathology 2007;31:854-69. [DOI: 10.1097/pas.0b013e31802efb45] [Cited by in Crossref: 121] [Cited by in F6Publishing: 25] [Article Influence: 8.1] [Reference Citation Analysis]
45 Ciocca V, Bombonati A, Palazzo JP, Schulz S, Waldman SA. Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. Histopathology 2009;55:182-8. [PMID: 19694825 DOI: 10.1111/j.1365-2559.2009.03358.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]